Skip to main content
Clinical Trials/NCT03272542
NCT03272542
Completed
Phase 2

Prebiotic Intervention to Improve Calcium Absorption After Gastric Bypass Surgery

San Francisco Veterans Affairs Medical Center1 site in 1 country20 target enrollmentNovember 21, 2017
ConditionsObesity

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Obesity
Sponsor
San Francisco Veterans Affairs Medical Center
Enrollment
20
Locations
1
Primary Endpoint
Change in fractional intestinal calcium absorption
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Gastric bypass surgery is a highly effective treatment for obesity, but it has negative effects on skeletal health, due in part to a dramatic decline in intestinal calcium absorption capacity. Animal and human studies suggest that non-digestible fibers termed prebiotics, such as soluble corn fiber (SCF), augment calcium absorption in the lower intestine as they act as substrates for beneficial gut microbiota. This is a pilot randomized controlled trial of the effects of SCF vs. placebo on intestinal calcium absorption, bone turnover marker levels, and the gut microbiome in postmenopausal women who have previously undergone gastric bypass surgery.

Detailed Description

The study is a pilot randomized control trial (RCT) of the effects of the prebiotic SCF vs. placebo in 20 postmenopausal women who underwent Roux-en-Y gastric bypass surgery 2-6 years previously and thus have completed the postoperative period of rapid weight loss and metabolic and dietary change. A 24 g/day dose of SCF85 (which is approximately 20 g/day fiber) will be tested, as that dose was proven effective for calcium absorption/retention in healthy postmenopausal women and adolescents. The SCF and the maltodextrin placebo will be mixed in water and consumed in divided doses twice daily for 2 months, a duration exceeding other SCF trials but remaining feasible for a pilot. The primary outcome will be change in intestinal calcium absorption, which is the efficacy outcome about which the study must collect preliminary data and from which the investigators must refine power calculations for the anticipated future trial. Because the investigators hypothesize that an increase in calcium absorption will decrease bone turnover and ultimately increase bone mineral density (BMD), the study will measure biochemical markers of bone turnover in this pilot. Secondary outcomes will be gastrointestinal tolerability and acceptability. On an exploratory basis, the study will determine effects of the prebiotic on the gut microbiome. This pilot will yield critical experience about feasibility of recruitment and adherence to the intervention and measurements.

Registry
clinicaltrials.gov
Start Date
November 21, 2017
End Date
January 31, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
San Francisco Veterans Affairs Medical Center
Responsible Party
Principal Investigator
Principal Investigator

Anne Schafer

Assistant Professor of Medicine and of Epidemiology and Biostatistics; Staff Physician

San Francisco Veterans Affairs Medical Center

Eligibility Criteria

Inclusion Criteria

  • Postmenopausal women (no menses for ≥4 yrs)
  • ≤ 75 yrs old,
  • Underwent Roux-en-Y gastric bypass surgery for weight loss 2-6 years prior

Exclusion Criteria

  • Serum 25(OH)vitamin D level \<30 ng/mL (to remove the effect of vitamin D insufficiency/deficiency)\*
  • History of \>1 bariatric surgical procedure
  • Antibiotic therapy in the last 3 months
  • Regular pre- or probiotic use in the last 3 months
  • Regain of \>50% of weight loss post-bypass
  • Calculated creatinine clearance \<30 mL/min
  • Serum calcium \>10.2 mg/dL
  • Use of hormone therapy, osteoporosis pharmacotherapy, glucocorticoids, or other medications impacting calcium metabolism
  • Thyroid stimulating hormone (TSH) \<0.01 milli-international units per liter (mIU/L)
  • A potential participant may be excluded if she has a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.

Outcomes

Primary Outcomes

Change in fractional intestinal calcium absorption

Time Frame: 2 months

Fractional calcium absorption to be determined using dual stable isotopic tracers

Secondary Outcomes

  • Acceptability(2 months)
  • Gastrointestinal tolerability(2 months)
  • Change in bone turnover markers(2 months)
  • Change in gut microbiome composition(2 months)

Study Sites (1)

Loading locations...

Similar Trials